Anti-HER2 x Anti-HER3 Bispecific Antibody (IgG-IgG) is designed to be generated by crosslinking two full length IgGs, anti-HER2 and anti-HER3 parental antibodies. A stable linkage is formed between the two antibodies. This BsAb can bind and inactivate two receptors simultaneously. It is designed for the research of Breast cancer; Gastric cancer; Prostate cacncer; Ovarian cancer; Solid tumors therapy.
Welcome! For price inquiries, we will get back to you as soon as possible.
INQUIRY